Treatment of clomiphene citrate-related ovarian cysts in a prospective randomized study. A single center experience.
OBJECTIVE
The present study aims to compare the effectiveness of placebo, low dose and very low dose oral contraceptives (OC) in the treatment of clomiphene citrate (CC)-related ovarian cysts.


METHODS
A prospective randomized placebo controlled study was undertaken at the Infertility Department of Dr. Zekai Tahir Burak Women's Health Education and Research Hospital. A total of 3250 primary infertile patients were administered CC for ovulation induction because of ovulatory dysfunction and/or unexplained infertility. One hundred and eighty-six women who were diagnosed with CC-related ovarian cysts greater than 20 mm on the third day of the following menstrual cycle, were eligible for the study. Group 1 (n = 62) was treated with very low dose OC (100 microg levonorgestrel + 20 microg ethinyl estradiol [EE]), group 2 (n = 62) with low dose OC (150 microg desogestrel + 30 microg EE) and group 3 (n = 62) with a placebo. The first control was 4 weeks later. Women with persistent cysts (n = 57) were called in 4 weeks later to continue the same treatment.


RESULTS
Demographic data were similar among the groups. At the first month, the regression rates of ovarian cysts were 64.5, 61.3 and 66.1% in groups 1, 2 and 3, respectively (P = 0.849). Among the 57 women (20, 19 and 18 from groups 1, 2 and 3, respectively) with persistent cysts, the regression rates were 65.0, 63.2 and 55.6%, respectively at the second month (P = 0.821). Persistence of ovarian cysts was significantly higher in women with a longer duration of CC treatment than in women with a shorter duration (P < 0.001).


CONCLUSIONS
Any treatment might be appropriate for patients with a CC-related ovarian cyst. However, there is no evidence to administer OC for treating CC-related ovarian cysts. Expectant management may also achieve similar success rates.
Department of Infertility, Dr Zekai Tahir Burak Women's Health Care Education and Research Hospital, Ankara, Turkey. altinkayaozlem@yahoo.com
Sunduz Ozlem
SO
Altinkaya
Betul Bayir
BB
Talas
Tayfun
T
Gungor
Cavidan
C
Gulerman
D000328:Adult; D000704:Analysis of Variance; D015992:Body Mass Index; D016009:Chi-Square Distribution; D002996:Clomiphene / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000008:administration & dosage; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D016912:Levonorgestrel / Q000008:administration & dosage*; D010048:Ovarian Cysts / Q000139:chemically induced* / Q000188:drug therapy*; D011446:Prospective Studies; D016896:Treatment Outcome
D003280:Contraceptives, Oral, Synthetic; D004967:Estrogens; D005300:Fertility Agents, Female; D002996:Clomiphene; D004997:Ethinyl Estradiol; D016912:Levonorgestrel